Lipocine (LPCN)
(Delayed Data from NSDQ)
$4.66 USD
+0.18 (4.02%)
Updated Oct 4, 2024 04:00 PM ET
After-Market: $4.67 +0.01 (0.21%) 7:22 PM ET
3-Hold of 5 3
F Value D Growth A Momentum F VGM
Price, Consensus and EPS Surprise
LPCN 4.66 +0.18(4.02%)
Will LPCN be a Portfolio Killer in October?
Zacks Investment Research is releasing its prediction for LPCN based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for LPCN
Lipocine (LPCN) Is a Great Choice for 'Trend' Investors, Here's Why
Here's Why Momentum in Lipocine (LPCN) Should Keep going
LPCN: What are Zacks experts saying now?
Zacks Private Portfolio Services
Other News for LPCN
Lipocine to Present at H.C. Wainwright 8th Annual MASH Investor Conference
Lipocine Announces Phase 2 Data on LPCN 2401 to be Presented at ObesityWeek?
Lipocine to Present at H.C. Wainwright 26th Annual Global Investment Conference
LPCN Stock Earnings: Lipocine Beats EPS, Misses Revenue for Q2 2024
Lipocine Announces Financial Results for the Second Quarter Ended June 30, 2024